Slides
Page 1
1 Strengthen the Bedrock, Break Through to Value Creation Fosun International 2026 Interim Results 2026-08-28 | Hong Kong
Page 2
22 Disclaimer This document is not intended to provide a full explanation of any relevant matters of Fosun International Limited (“Fosun” or the “Company”). You must refrain from relying on any information set out in this document. No statement, guarantee or undertaking is or will be made or given at present or in the future in respect of the accuracy, fairness, reasonableness, correctness or completeness of this document or any information or opinions set forth herein or any other information or opinions, whether written or oral, available to any stakeholder or its advisers, nor is there or will there be any express or implied indication made in respect of the above content at present or in the future. None of the Company or any of its shareholders, directors, officers, employees, affiliates, advisers or representatives (the “Parties”) shall assume any liability, including but not limited to liability for default, for or in respect of the above content at present or in the future. The Parties expressly state that they shall not be held liable for any loss resulting from the use of this document or its content or in any other manner in connection with this document. It is assumed that information set out in this document is appropriate for the current situation and such information could be subject to change without notice. None of the Parties shall be held liable for procuring the receipt of information under this document by any recipients, updating information under this document, or correcting any manifest error contained under this document. In the event of any conflict between this document and the 2026 interim results announcement or the 2026 interim report of the Company (the “Semi-Annual Documents”), the Semi-Annual Documents shall prevail. Cautionary Statement Regarding Forward-Looking Statements This document includes forward-looking statements. All statements, other than statements of historical facts, that address activities, events or developments that Fosun International Limited expects or anticipates will or may occur in the future (including but not limited to projections, targets, estimates and business plans) are forward-looking statements. The Company’s actual results or developments may differ materially from those indicated by these forward-looking statements as a result of various factors and uncertainties, and other risks and factors beyond our control. In addition, the Company makes the forward-looking statements referred to herein as of today and undertakes no obligation to update these statements. Unless otherwise stated, the financial figures of 2026H1 in this document are calculated using the average exchange rate for the reporting period of January to June 2026 (USD/CNY=6.89649, HKD/CNY=0.88155, EUR/CNY=8.03000). Period-end exchange rate refers to the rate of 2026/6/30 (USD/CNY=6.81090, HKD/CNY=0.86860, EUR/CNY=7.76710).
Page 3
33 Table of Contents 01. 02. 03. Financials Business Strategic Development
Page 4
44 1 Core companies include Fosun Pharma, Yuyuan, Fosun Insurance Portugal and Fosun Tourism Segment (In this report, the Fosun Tourism Segment includes Club Med, Atlantis Sanya and Vacation Asset Management Center, consistent with the scope of Fosun Tourism Group as defined in the 2025 Annual Results) 2 Countries and regions with revenue exceeding RMB 50 million in 2026H1 3 Industrial Operating Profit includes the profit contribution from operation subsidiaries, associates and joint ventures which are under equity method accounting 86.96 RMB Billion Remained stable, up by 3% YoY excluding the impact of HAL’s deconsolidation 4.20 RMB Billion Up by 16.7% YoY, focus on R&D system optimization, R&D efficiency improvement, continuous investment in advantageous pipelines/product lines 3.69 RMB Billion Up by 17% YoY, driven by improved profitability in the insurance segment and Hainan Mining 63.88 RMB Billion Four Core Revenues1 49.16 RMB Billion 1.72 RMB Billion Up by 160.3% YoY, driven by higher industrial operating profit and lower headquarter finance costs Total Revenue Overseas Revenue Investment in Technology and Innovation Industrial Operating Profit3 Net Profit Attributable to Owners of the Parent 73.5% of total Group revenue, maintaining stable Revenue increased by 4.6% YoY, excluding the impact of Yuyuan Up by 5.3% YoY, 56.5% of total Group revenue, up by ~3 ppts YoY Covering 40+ countries and regions2 1. Financials 2. Business 3. Strategic Development Resilient Performance of Core Industries, Back on a Profit Growth Track
Page 5
55 Portfolio Quality Continues to Strengthen, with Valuation Recovery Underway Group Portfolio Value (PV)1 as of Period-End 1 Group Portfolio Value (PV) = Market Value of Group-level Listed Companies + Fair Value of Group-Level Unlisted Companies on the Most Recent Transactions Method or Comparable Corporate Method 2 Adjusted NAV (Net Asset Value) = Group Portfolio Value – Group-level Net Debt, as of August 26, 2026 192.0 Billion/RMB Share of Listed and Insurance Assets in Portfolio Value 25.06.30 26.06.30 49% Book Value per Share2 13.5 HKD 0.39 P/B Net Assets Attributable to Owners of the Parent as of Period-End 95.2 RMB Billion Adjusted NAV as of Period-End 128.0 RMB Billion Adjusted NAV2 per Share 18.1 HKD 0.29 P/NAV Enhanced ROE Management, Improved Core Business Performance Medium-term target: The Group’s net profit attributable to owners of the parent reaches RMB 10 billion or above Core businesses delivered strong performance in 2026H1, with net profit attributable to owners of the parent up by 160.3% YoY to RMB 1.72 billion Financial Strategy Drives Steady Growth in Portfolio Value and Paves the Way for Further Valuation Recovery Disposal of Non-Core Assets, Commitment to Deleveraging Medium-term target: Reducing group level’s interest-bearing liabilities to below RMB 60 billion Group-level interest-bearing liabilities had decreased by about RMB 4.5 billion from the beginning of the year as of June 2026 Asset Spin-off to Unlock Value To actively spin off unlisted assets and push forward public listing, elevate portfolio transparency, and unlock valuation re-rating Sanya Atlantis has submitted application for commercial real estate REITs issuance, and several subsidiaries inside Fosun ecosystem are in the public listing process. 55% Portfolio Value Remained Stable: Higher Share of Quality Assets and Steady Valuation Recovery 1. Financials 2. Business 3. Strategic Development
Page 6
66 24.03 RMB Billion 2026H1 Revenue 6.5% YoY Growth 760 RMB Million Industrial Operating Profit 3% Comparable- Basis Growth Health Accelerated global operations, with growth in both scale and revenue contribution: Overseas revenue reached nearly RMB 10 billion, up by 16% YoY, accounting for about 41.5% of total revenue Henlius HLX14 secured marketing approval in Canada following U.S. and EU approvals, while HLX11 was approved in the EU; Fosun Health actively explores international healthcare services, with rapid growth in the number of overseas patients 31.63 RMB Billion 2026H1 Revenue 6.2% YoY Decline 50% YoY Growth Happiness Breakthroughs in globalizing our brands: Nanxiang opened 3 new overseas stores, while Lao Miao Jewelry opened 5 new overseas stores2 Revitalization of Grand Yuyuan: Seamless integration of scenario and experiences, attracting over 19 million visitors and generating GMV of more than RMB 2.2 billion Club Med continued to expand global footprint; Atlantis Sanya sustain overwhelming popularity with record-breaking Spring Festival performance, and double digit revenue growth in 2026H1 27.31 RMB Billion 2026H1 Revenue 8.1% Comparable- Basis Growth 2.96 RMB Billion Industrial Operating Profit 15% YoY Growth Wealth Strong growth in the insurance segment: Four insurance subsidiaries in China and overseas recorded total premiums of around RMB 52.7 billion, up by 24% YoY, with combined industrial operating profit of about RMB 2 billion Launched 5 new private equity funds, with private equity fund AUM exceeding RMB 43 billion; focused on high-growth sectors including AI and biopharma, with 16 portfolio companies listed and 10+ companies having filed for IPOs 4.61 RMB Billion 2026H1 Revenue 14.6% YoY Growth 180 RMB Million Industrial Operating Profit 54% YoY Growth Intelligent Manufacturing Hainan Mining: Revenue and net profit attributable to owners of the parent both grew by double digits in 2026H1; achieved a “0 to 1” breakthrough in Renewable Energy Segment expanded its fluorite business footprint and strengthened its strategic resource reserves Wansheng: The Thailand production base commenced operations smoothly, further strengthening its global supply chain; exploring opportunities in specialty chemicals along the AI supply chain, with sales of flame retardants for copper clad continuing to grow 320 RMB Million Industrial Operating Profit of Core Companies1 ¹ Core companies in the Happiness segment include Yuyuan and Fosun Tourism Segment ² Overseas Lao Miao Jewelry stores include duty-free locations, stores in Hong Kong and Macao, and other overseas stores; the same applies hereinafter. Steady Performance Across Four Segments, Enhanced Industrial Operating Capabilities 1. Financials 2. Business 3. Strategic Development
Page 7
77 Driving growth from Core Subsidiaries, Establishing a Strong Base for Sustainable Profitability Yuyuan’s revenue is based on the Chinese Accounting Standards; financial data was converted at the average exchange rate of 2026H1; unless otherwise specified, all amounts are denominated in RMB Key project breakthrough: Deepening the global partnership with AriBio for AR1001, with an option to expand development and commercialization rights to key markets including the U.S., Europe and Japan Advancing globalization and innovation: Overseas revenue exceeded 30%, Innovative Drug revenue grew by 14% YoY, representing an increase of ~2 ppts in total revenue share Yuyuan : “Oriental Lifestyle Aesthetics” Strategy to Drive Stabilization and Recovery Lao Miao Jewelry improves quality and efficiency: Overseas revenue rose by over 200% YoY,with piece- price product sales exceeding 18%, driving significant improvement; gross profit margin increased by 1.26 ppts YoY Building oriental culture IP: The Year of the Horse Lantern Festival connected the entire Grand Yuyuan area for the first time, with visitor traffic up by over 10% YoY 3.88 Billion EUR 2026H1 Premium 165 Million EUR 2026H1 Net Profit Attributable to Owners of the Parent Market leader in Portugal with 30% market share; strong performance in domestic auto and life insurance drove total premiums up by 21% YoY Continued expansion into potential markets including Europe, Latin America, and Africa; total premium for international business grew by double digits S&P rating outlook upgraded from “Stable” to “Positive” >850 Million 2026H1 Revenue of Atlantis Sanya Club Med: Continued to deepen global presence and upgrade resort experiences, with the opening of Hangzhou Longwu Resort and the soft opening of South Africa Beach & Safari Resort Atlantis Sanya: Revenue in 26H1 exceeded RMB 850 million, delivering double-digit growth, with average occupancy exceeding 87% and a continued increase in overseas visitors 4.5% Gross Profit Margin YoY Growth Fosun Pharma: Innovation with global expansion drives Innovative Drug growth Fosun Insurance Portugal: Market Leader in Portugal with Global Expansion Fosun Tourism Segment: Focus on three major product lines To become a benchmark insurer in its markets To become the world’s largest leisure & vacation lifestyle brand To become a C-MNC in the biopharmaceutical industry To become a world-class family-oriented consumer group rooted in China 5% YoY Growth 20.38 Billion 2026H1 Revenue 1.72 Billion 2026H1 Net Profit Attributable to Owners of the Parent 17.02 Billion 2026H1 Revenue 160 Million 2026H1 Net Profit Attributable to Owners of the Parent 157% YoY Growth 4% YoY Growth >10% YoY Growth 9.92 Billion 2026H1 Revenue 19% YoY Growth 24% YoY Growth 1. Financials 2. Business 3. Strategic Development
Page 8
88 Peak Re Rating Upgrade: Moody’s upgraded the Insurance Financial Strength Rating from Baa1 to A3 International Footprint: Deepened its presence in India while expanding into Europe and North America Net profit in 2026H1 increased by 270% YoY Strong growth in new business premiums: Individual agent channel premiums increased by 68% YoY, while bancassurance channel premiums rose by 226% YoY Net profit in 2026H1 grew significantly Ecosystem Synergies: Leveraged the Group’s ecosystem resources to build a differentiated, full-lifecycle healthcare management system Maintained a sound balance sheet, with total capital adequacy ratio at 19.3% and CET1 ratio at 15.1% as of June 2026 NPL ratio declined to 2.2% as of June 2026, continuing a downward trend 26H1 Net profit surpassed the full-year 2025 level, up by 83% YoY Seizing market opportunities from rising lithium salt and crude oil prices, achieving structural breakthroughs and high-quality growth Unless otherwise specified, all amounts are denominated in RMB, Net Profit figures refer to Net Profit Attributable to Parent Company. Strong Growth at Next-tier Core Companies Unlocking Profit Upside Pramerica Fosun Life Insurance Fosun United Health Insurance Millennium BCP Hainan Mining 1.19 Billion USD 2026H1 Total Premiums 12% YoY Growth 90 Million USD 2026H1 Net Profit 8.38 Billion 2026H1 Total Premiums 52% YoY Growth 780 Million 2026H1 Net Profit 4.96 Billion 2026H1 Total Premiums 36% YoY Growth 570 Million 2026H1 Net Profit 12.7% YoY Growth 14.6% 2026H1 ROE 2.72 Billion 2026H1 Revenue 13% YoY Growth 510 Million 2026H1 Net Profit 570 Million EUR 2026H1 Net Profit 1. Financials 2. Business 3. Strategic Development
Page 9
99 Global Operations Driving High-Quality Growth, Technology Innovation Enhancing Efficiency Global In-Depth Operations Innovation-Driven Growth 53% 2025H1 47% 2024H1 >56% 2026H1 “AI + Business” deepens AI applications across industries Fosun Pharma's oral small-molecule DPP-1 inhibitor secured an exclusive global licensing deal outside Chinese Mainland, Hong Kong and Macao Henlius' PD-1 monoclonal antibody secured an exclusive licensing deal in Japan Biopharma: Global Expansion of Innovation Increased investment in innovation to accelerate R&D Henlius’ proprietary next-generation rHuPH20 injection, powered by the “AI for Science” platform, shortened the R&D cycle from 18 months to 5 months and received clinical trial approval in China in March 2026 AI G.O in tourism business provides 24/7 multilingual and personalized online services Fosun United Health Insurance’s proprietary AI products, including “He Wu Ji” and “Lv Xing Jia”, transformed the claims experience; Finloop achieved fully automated AI-powered information processing with zero human intervention 7 Innovative Drugs with a total of 20 indications independently developed and licensed-in by Fosun Pharma achieved positive progress, with R&D investment in 2026H1 reaching RMB 3.247 billion, up by 25.66% YoY Innovative Drug revenue in 2026H1 exceeded RMB 4.9 billion, up by 14% YoY Over 30 portfolio companies of Fosun Capital and Fosun RZ Capital showcased at WAIC 2026, spanning AI infrastructure, embodied AI, memory chips and quantum computing Fosun Health Capital successfully launched New Drug Fund II with RMB 2 billion raised, further strengthening its focus on early-stage innovation Lao Miao Jewelry added 5 overseas stores, while Nanxiang added 3 overseas stores Club Med deepens its global presence as its South African resort soft-opens in July; Atlantis Sanya’s revenue from international source markets grew strongly Cultural Tourism Consumption: Global Expansion of Brands Financial Insurance: Deepening Global Presence Fosun Insurance Portugal’s premiums for international business achieved double- digit growth, gaining leading positions in multiple markets including Peru, Bolivia and Chile Intelligent Manufacturing: Global Supply Chain Hainan Mining actively explored global resource through projects including Mali Lithium and Oman Oilfield Wansheng commenced operations of its Thailand production base Rising Overseas Revenue Share Capturing unicorn opportunities through PE/VC 1. Financials 2. Business 3. Strategic Development
Page 10
1010 Sound Balance Sheet, Stable Credit Rating 1 Group-level onshore and offshore financing amount, offshore financing at the average exchange rate of 2026H1, incl. the 590 USD million offshore syndicated loan signed by Fosun International before the end of June 2026 Public Markets Financing During the Period1 5.22 RMB Billion Excl. consolidated subsidiaries Amid rising global interest rates, the Group has proactively optimized the pace of its offshore bond issuance Stable Credit Ratings with Investment-grade target unchanged In May 2026, S&P Global Ratings affirmed Fosun International’s BB- rating with a stable outlook in its annual rating review. The report recognized Fosun's continuing improvements in credit profile, capital structure and liquidity The Group will continue to advance asset disposal, reduce holding companies’ debt, and improve financial metrics, remaining firmly committed to its investment-grade target Average Cost of Debt During the Period 5.2% Excl. consolidated subsidiaries Down by 10bps compared with year-end 2025 Cash and Bank Balances as of Period- End (Consolidated) 61.21 RMB Billion Remained stable Average Cost of Debt During the Period (Consolidated) 5.0% Remained stable 1. Financials 2. Business 3. Strategic Development Financing Costs Remain Stable Despite the Rebound in Global Interest Rates 5.6% 5.3% 5.0% 5.0% 4.6% 4.8% 5.0% 5.2% 5.4% 5.6% 5.8% 2024 2025H1 2025 2026H1
Page 11
1111 Ongoing Non-Core Divestments and Firm Deleveraging Commitment Asset divestments at the Consolidated Level Further Reduction in Group Interest-Bearing Debt 2025.12.31 vs 2026.06.30 Medium-term target 89.9 RMB Billion <60 RMB Billion 85.41 RMB Billion Fosun International Center in Jinan Disposed Fosun International Financial Center, a 260-metre landmark office tower in the core area of Jinan CBD with GFA of approximately 126,000 sq.m., to Fuze Life Insurance COURT Hotels in Japan Disposed of 13 non-core business hotels in regional cities from the COURT hotel portfolio, retaining only assets with synergies with the Group 40% Equity Interest in Luz Saúde Fidelidade sold its 40% stake in Portuguese private healthcare group Luz Saúde, S.A. for over EUR 300 million, while retaining a 59.86% controlling stake Multiple Divestments of Minority-Investment Subsidiaries and private-equity platforms divested multiple minority investments in the Intelligent Manufacturing and Health segments through equity transfers, secondary-fund transactions and other channels, contributing to Group cash inflows 1 Incl. the USD 590 million offshore syndicated loan signed by Fosun International before the end of June 2026 Ongoing Non-Core Divestments and Firm Deleveraging Commitment Cash inflows from asset divestments and dividend upstream at the Group level Contracted divestments of heavy assets, non-core and non- strategic assets by subsidiaries ~9.3 RMB Billion ~7 RMB Billion 1. Financials 2. Business 3. Strategic Development
Page 12
1212 Clear Financial Strategy for Long-Term Value Growth Focused Development Focus on competitive industries including Biopharma and Insurance Segment, develop to become industry leaders Improve global operations to steadily increase the share of overseas revenue Increase investment in innovation and deepen AI applications Profit Growth Medium-term target: The Group’s net profit attributable to owners of the parent reaches RMB 10 billion or above Enhance operating efficiency of core companies and strengthen ROE management Reduce headquarters expenses Deleveraging Medium-term target: Reduce the Group's interest-bearing liabilities to below RMB 60 billion Continue divestments of non-core assets, enhance subsidiary dividend management and accelerate cash inflows Advance toward investment-grade status Shareholder Returns Completed approximately HKD 250 million in Fosun International share buybacks in 2026H1 Target payout ratio increased to 35%, with the dividend for the fiscal year 2026 expected to be no less than HKD 1.5 billion Major shareholders and management intend to purchase up to HKD 500 million of shares by March 30, 2027 Medium-Term Financial Strategy and Targets 1. Financials 2. Business 3. Strategic Development
Page 13
1313 Table of Contents Financials01. Business02. Strategic Development03.
Page 14
14
Page 15
1515 v v v Luz Saú de v v v Health 61% 8% 31% Pharmaceuticals Med Tech Healthcare Services & Consumptions Revenue grew + 6.5% YoY, mainly driven by the YoY increase in Fosun Pharma and Luz Saúde’s revenue Industrial operating profits reached RMB 760 million, with a comparable-basis growth of 2.7% v Fosun Health continued to advance internationalization and expanded into Indonesia, Bangladesh, Mongolia, HK and Macao regions Foshan Fosun Chancheng Hospital ranked No.1 on the Alibi Social-run hospital Competitiveness Ranking for the 8th consecutive year Jianjia Healthcare further strengthened its nationwide footprint, achieving significant revenue growth and advancing medical specialty development, maintaining a leading position in the rehabilitation sector Health Segment Business Highlights 1. Financials 2. Business 2.1 Health 3. Strategic Development 2026H1 Total Revenue Fosun Pharma Henlius Globalization Fosun Pharma R&D Expenditure Fosun Health & JianJia Healthcare 24.03Billion/RMB Revenue 20.38 Billion/RMB Revenue 3.59 Billion/RMB Overseas Revenue 10 Billion/RMB 3.25 Billion/RMB Revenue3.74 Billion/RMB Revenue 0.45 Billion/EUR Revenue grew by 13.4% YoY, mainly driven by the growth of the company's medical service activities Relying on high-quality and professional operations, achieved a net operating profit of EUR 29 million, +21.3% YoY R&D expenditure in Pharma segment reached RMB 3.046 billion R&D expenditure in Innovative Drugs reached RMB 2.650 billion, +48.38% YoY, accounting for 81.61% of total R&D, +12.50 ppts YoY The overseas revenue grew +16% YoY, accounted for 41.5% of total Revenue grew +27.3% YoY Net profit was RMB 430 million, +10.33% YoY Global Product Revenue reached RMB 2.939 billion, +14.9% YoY Innovative Drug revenue reached RMB 4.911 billion, +13.84% YoY; accounting for 33.35% of Pharma segment revenue, +2.12 ppts YoY
Page 16
1616 Fosun Pharma: Rising Share from Innovative Drug and Overseas Revenue Revenue 100 Million/RMB Net Profit Attributable to Shareholders 146.01 138.17 147.27 20.69 19.53 18.59 36.57 35.89 37.35 24H1 25H1 26H1 12.25 17.02 17.21 24H1 25H1 26H1 100 Million/RMB Net Profit ex Non-recurring 100 Million/RMB Net Operating Cash Flow 12.54 9.61 11.44 24H1 25H1 26H1 100 Million/RMB Pharma Med Tech Healthcare 19.07 21.34 24.24 24H1 25H1 26H1 Revenue • Increased +7.32% YoY on a constant currency basis • Innovative Drug revenue reached RMB 4.911 billion, +13.84% YoY ,accounting for 33.35% of Pharma segment revenue • Overseas* revenue reached RMB 6.379 billion, +16.45% YoY ,accounting for 31.30% of total revenue Net Profit Attributable to Shareholders • Net profit attributable to shareholders was RMB 1.721 billion, +1.15% YoY • Net Profit ex non-recurring gains or losses: RMB 1.144 billion, +19.09% YoY; +21.97% YoY on a constant currency basis Net Operating Cash Flow • Net operating cash flow grew +13.59% YoY • Driven by steady growth in revenue 1. Financials 2. Business 2.1 Health 3. Strategic Development Note*：Revenue from countries and regions outside Chinese mainland
Page 17
1717 Overseas Revenue * 6,379 Million/RMB +16.45% 31.30%YoY % of total revenue (+3.1 pcts) The process of internationalization continues to advance, and breakthroughs have been made in global market expansion Serplulimab Injection(PD-1) was approved in EU Desuzumab was approved in Canada, following by its approval in the U.S. and EU Pertuzumab was approved in EU Gland Pharma's new products such as Dabavanxin and bromonidipine have been approved in the U.S. Gland Pharma has entered into a strategic manufacturing and supply agreement with a global pharmaceutical company, with the expected annualized revenue potential after commercialization of all products at approximately USD 90 million to USD 100 million The new Breas Apto respiratory mask series has been launched in Europe, and its U.S. registration filing is also progressing steadily Registration: Europe- and U.S.-led breakthroughs and deep penetration in emerging markets It has established a registration network covering core global markets including China, the United States, Europe, Japan, India, Africa, Southeast Asia, and the Middle East Serplulimab has been approved for marketing in 50+ countries The biopharmaceutical platform's quality system and registration capabilities have been certified to international standards,achieving deep coverage of mainstream markets in Europe and America Fosun Pharma USA further expanded innovative drug registration and commercialization capabilities Production: Global layout with strengthened supply foundation The Pharma segment has 65 manufacturing sites / production lines have obtained GMP and WHO PQ certification from mainstream markets such as the United States, European Union, and Japan Henlius biopharmaceutical production lines have achieved regular supply in China, Europe, Canada, Latin America, Southeast Asia, India, and other regions Core Competitiveness Innovative R&D: Deepening global clinical collaboration to accelerate product value transformation We continuously conduct multiple international multicenter clinical studies, covering the United States, the European Union, Japan, Australia, and other regions Promote international multicenter Phase II clinical trials on FXS6837 (CFB) and FXS7553 (DPP-1) Serplulimab (PD-1), HLX22 (HER2), HLX43 (PD-L1 ADC), and others have received FDA/EMA orphan drug designation Note*：Revenue from countries and regions outside Chinese mainland 1. Financials 2. Business 2.1 Health 3. Strategic Development Fosun Pharma: Building a Global Operational System with Full Value Chain Collaboration
Page 18
1818 Global commercialization team: ~6,000 people China: ~5,000 Market Access Team Oncology Innovative Drugs ~2,000 person Non-Oncology Innovative Drugs OBM Broad Market New Retail Team for OTC Med Tech Team Overseas: ~1,000 Core Markets • Coverage of 16,000+ secondary and above hospitals Broad Markets • Covering 130,000+ primary terminals Retail Markets • Covering 200,000+ pharmacies Emerging markets Mature markets • US Market: Actively promoting the sale of generic drugs and preparations for the launch of innovative drugs, respiratory and medical aesthetic devices, and continuously strengthening commercialization capabilities in the U.S. market • EU Markets: Serplulimab Injection has been included in the healthcare insurance catalogs of 12 EU countries • Japanese Market: Collaborated with Eisai on Serplulimab to accelerate its commercialization process in Japan Med-Tech • Sisram: Combining "digitalization + direct distribution," it has established 12 direct sales offices worldwide, with a marketing network covering more than 110 countries and regions • Breas: Established 9 subsidiaries worldwide, with a marketing network covering nearly 60 countries and regions • African Markets: A marketing network covering more than 40 countries and regions has been established • Middle East Markets: Accelerate the launch of innovative products through strategic cooperation JV: Established a joint venture in Saudi Arabia with Saudi pharmaceutical company SVAX to promote innovative and high-value products entering the MENAT region (the Middle East, North Africa, Turkey) Licensing: Collaborated with Abbott, granting exclusive commercial licenses for Serplulimab injection in 42 countries/regions across Asia, the Middle East, Africa, and Eastern Europe, deepening its presence in emerging markets 1. Financials 2. Business 2.1 Health 3. Strategic Development Fosun Pharma: Continued Strengthening Global Commercialization Capability
Page 19
1919 • Focused on 3 core therapeutic areas: oncology, immuno-inflammatory diseases, and neurodegenerative diseases, while actively expanding into chronic diseases (cardiovascular, renal, and metabolic), anti-infective, and rare disease treatments • Strengthened core technology platforms such as antibodies, ADCs, and next-generation small molecule drugs, and actively expanded into cutting-edge technology areas such as radiopharmaceuticals, small nucleic acids, peptides, and cell therapies Launched/NDA Phase III Phase II Phase I Launched（Diagnostic & Med Tech）IIT/Pre-clinical Monoclonal Antibody Bis, Poly Antibody ADC Fusion Proteins Small Molecules PROTAC/ Molecular Glue Autologous CAR-T Next-Gen CAR-T1 RLT siRNA Others2 Diagnostic & Med Tech Solid Tumors Heme CNS Immuno- Inflammatory Diseases CVRM Others （Including rare diseases, anti - infections, etc） Note1: Including In-vivo CAR-T and U CAR-T Note2: Including recombinant proteins, immunoglobulins, cytokines, botulinum toxin, FDCs, peptides, tumor vaccines, etc. 1. Financials 2. Business 2.1 Health 3. Strategic Development Fosun Pharma: Comprehensive Deployment of Innovative Technology Platforms
Page 20
2020 TAs Platforms Molecule Indications IND Ph1/ IIT Ph2 Ph3 NDA/ BLA Launched Solid Tumors Antibody/ADC HLX10 (PD-1) sqNSCLC, ES-SCLC, ESCC, nsNSCLC, GC 1L LS-SCLC 1L ES-SCLC | US JP mCRC HLX22 (HER2) GC, BC HLX43 (PD-L1 ADC) Solid tumors HLX48 (EGFR/cMet ADC) SCLC, CRC FXB0871 (PD-1/IL2) Solid tumors Small Molecule FCN-159 (MEK1/2) NF1-Pediatric, LCH-Adult/Pediatric NF1-Adult LGG FXS4640 (PLK1) Solid tumors RLT SRT-007 (PSMA) mCRPC Heme Antibody GR1803 (BCMA/CD3) MM Small Molecule FXS0683 (BCL-2) Hematology Cell Therapy FKC876 (CD19 CAR-T) LBCL FKC889 (CD19 CAR-T) ALL, MCL FKC389 (BCMA/CD19) Hematology, Autoimmune diseases Immuno- Inflammatory Diseases Antibody JS005 (IL-17A) PsO Small Molecule FXS5626 (TKY2/ JAK1) NIU FXS6837 (CFB) IgA PNH FXS7553 (DPP1) NCFBE COPD Cell Therapy FKC289 (CD19/BCMA CAR-T) ALA, MN Neurodegenerative Diseases Small Molecule FXS4983/AR1001 (PDE5) AD GV-971 AD HT-001 (NLRP3) PD CVRM siRNA FXR0906 (ApoC3) sHTG 1. Financials 2. Business 2.1 Health 3. Strategic Development Fosun Pharma: Building a High-Value Pipeline Portfolio
Page 21
2121 License out* Note*: Not all cases are included Co-Development Partner Nominations Pre-clinical - - Up to USD 362.5 Million per project Global（Excluding Chinese Mainland, Hong Kong, and Macau） License In* AR1001 JS005 PDE5 IL-17A Phase III NDA AD Psoriasis USD 60 Million Exercise fee USD 80 Million RMB 215 Million USD 100 Million RMB 1,125 Million Global Main Markets Greater China Region Fund Incubation* HT001+HT002 GalNAc siRNA+ HBsAg monoclonal antibody Phase II Chronic hepatitis B • Fosun Health Capital Incubated • Valuation exceeds RMB 2,000 million after Series B equity financing • Fosun Pharma holds 20.87% By integrating independent R&D, cooperative development, licensing and introduction, fund incubation, and industrial investment, the company continuously enriches its innovative product pipeline and accelerates the transformation and implementation of innovative technologies and products Pipelines YP05002 Cetuximab Evolocumab Belimumab HLXTE-HAase1001 Serplulimab Target GLP-1 - PD-1 Clinical Stage Phase I - Bridging Indications T2DM, Obesity - Tumors Upfront USD 150 Million USD 77 Million USD 75 Million Potential Milestones USD 1,935 Million USD 245 Million USD 313 Million Licensed Area Global Global (Excluding Chinese Mainland, Hong Kong, Macau, and Taiwan） Japan 1. Financials 2. Business 2.1 Health 3. Strategic Development Fosun Pharma: Establishing An open Innovation Ecosystem
Page 22
2222 Fosun Pharma: Evolution of the Medical Service & Healthcare Management Model General Healthcare • Advancing GBA General Hospital integrated management: Strengthening integrated collaboration and management among regional healthcare, operations and information systems. Leveraging the “Hong Kong and Macau Medicine and Equipment Connect” to introduce nearly 100 global cutting- edge innovative drugs and medical devices • Smart healthcare and AI: Implementing AI across key scenarios including patient services, clinical support, Group management and international healthcare, improving overall operational efficiency. Guangdong Pharmaceutical University Guangzhou Fosun Chancheng Hospital became the first specialized AI healthcare ecosystem partner hospital in China to join Ant Afu • International expansion: Actively expanding into markets including Indonesia, Bangladesh, Mongolia, Hong Kong and Macau. The standalone medical building of Foshan Fosun Chancheng Hospital’s International Medical Center commenced operations, establishing an integrated international healthcare service model covering outpatient care, inpatient services, health check- ups and rehabilitation Rehabilitation Healthcare • Steady nationwide expansion: Operating 25 rehabilitation medical institutions (23 controlled and 2 asset-light operations), with 2 new asset-light operation projects added • Advanced specialty development: Strengthening three subspecialties of neurorehabilitation, critical care rehabilitation, and orthopedic rehabilitation and ten rehabilitation technology bases, while introducing cutting-edge technologies including brain-computer interfaces, intelligent rehabilitation equipment and exoskeleton robots • AI-enabled applications: AI-powered clinical quality control, AI- powered medical insurance review, the proprietary ST pathology language model and AI rehabilitation managers • Improved commercial insurance ecosystem: Establishing a diversified payment network, partnering with major insurers and building a three- in-one commercial insurance service system China Conference Southeast Asia 2026 (CCSEA) Overseas Medical Outreach Activities 1. Financials 2. Business 2.1 Health 3. Strategic Development
Page 23
2323 Fosun Pharma: Medical Devices & Diagnostics 的全球领先的能量源医疗 美容设备供应商 战略布局美容牙科、注射 填充、个人护理等赛道， 打造美丽健康生态 长效肉毒素医美适应症国 内申报上市（待确认）； 推出首款家用美容仪器； 推出Alma Ted等差异化设 备；推进透明质酸钠溶液 产品国内临床，主打祛颈 纹 的全球领先的能量源医疗美容 设备供应商 战略布局美容牙科、注射填 充、个人护理等赛道，打造美 丽健康生态 长效肉毒素医美适应症国内申 报上市（待确认）；推出首款 家用美容仪器；推出Alma Ted 等差异化设备；推进透明质酸 钠溶液产品国内临床，主打祛 颈纹 Aesthetic Medical Dual-engine strategy of “energy-based devices + injectable filler,” accelerating global expansion Energy-based devices Apart from overall growth in North America markets, core product lines (Soprano, Hybrid and Alma Harmony) delivered solid performance and positive market feedback Injectable filler Daxxify (Botulinum toxin type A for injection) continued to advance its commercialization in China, with cumulative sales exceeding 30,000 vials and coverage across nearly 500 premium aesthetic institutions during the reporting period Soprano Titanium Alma PrimeX BeautiFill by Lipolife Alma Harmony Daxxify Profhilo Revanesse Professional Medical Device 的全球领先的能量源医疗美容 设备供应商 战略布局美容牙科、注射填 充、个人护理等赛道，打造美 丽健康生态 长效肉毒素医美适应症国内申 报上市（待确认）；推出首款 家用美容仪器；推出Alma Ted 等差异化设备；推进透明质酸 钠溶液产品国内临床，主打祛 颈纹 Fosun Insightec In 2026H1, 2 systems were newly sold in China, with one system installed and over 200 surgeries completed Intuitive Fosun Installed 6 systems across Chinese mainland, Hong Kong and Macau The next-generation da Vinci 5 robotic surgical system completed its first installation in Hong Kong and was included in the NMPA’s Special Review Procedure for Innovative Medical Devices Respiratory Care 的全球领先的能量源医疗美容 设备供应商 战略布局美容牙科、注射填 充、个人护理等赛道，打造美 丽健康生态 长效肉毒素医美适应症国内申 报上市（待确认）；推出首款 家用美容仪器；推出Alma Ted 等差异化设备；推进透明质酸 钠溶液产品国内临床，主打祛 颈纹 A well-known European ventilator manufacturer Business operations cover nearly 60 countries and regions worldwide U.S. market growth was temporarily impacted by health care policy changes Other regional markets remained resilient, with rapid penetration growth in key markets including Japan and Europe The new Breas Apto respiratory mask series was launched in Europe, while its its U.S. registration filing is also progressing steadily The self-developed STD Urine Nucleic Acid Quadruple Test received marketing approval, becoming China’s first four-in- one urine nucleic acid testing solution for STDs (covering UU, CT, NG, MG, using fluorescent PCR). Through non-invasive sampling and multiplex testing, the solution enhances genitourinary infection detection and has been adopted in Grade-A Tertiary hospitals The new High-Speed Direct-Connect Laboratory Automation Line F-A6200 was launched, featuring a compact design, flexible configurations and optimized workflows to accelerate laboratory automation upgrades Fosun Diagnostics 1. Financials 2. Business 2.1 Health 3. Strategic Development
Page 24
2424 • PharmAID® V2.0: PharmaSight for strategic decisions, Astrolabe & MedAlkaid for R&D, AquaVista for data & knowledge • AI tools already applied in early discovery; 2 new molecules generated and structured with AI-assisted had entered the PCC stage Four Platforms, One AI Backbone Across the Pharma Lifecycle Knowledge · Models · AgentsData GovernanceData IntegrationUnified Data LakehouseAquaVista Medical Review Data & Safety Regulatory WritingStudy Design AI for Clinical R&D & Medical Sciences MedAlkaid Property Prediction Dry-Wet Lab Loop Virtual Screening Molecule Design Target Discovery AI for Drug Discovery Astrolabe NDA/BLA & Post-LaunchPhase I–IIIPre-clinical / INDMolecule & CMCTarget Discovery & Validation Opportunity Assessment & Initiation Project Assessment Portfolio Management Quantitative Decisions Intelligence Analysis Decision IntelligencePharmaSight 1. Financials 2. Business 2.1 Health 3. Strategic Development Fosun Pharma: Driving Business Growth Through Digitalization and AI
Page 25
25
Page 26
2626 Fosun Tourism Segment Revenue continued to grow, driven by continuous improvement in global operating capabilities Performance rebounded, while core businesses remained fundamentally resilient Lean operations significantly improved gross margin and reduced administrative expenses Net profit attributable to owners of the parent reached RMB 160 million, up by 157 % YoY, driven by business transformation and innovation, optimized product mix and channel quality, and enhanced operational efficiency and profitability during the reporting period Happiness 68% 32% Brand Consumption Tourism Culture Revenue decreased by 6.2% YoY, primarily attributable to reduced revenue at Yuyuan and Lanvin Group Industrial operating loss reached RMB 200 million, loss down by 40% YoY, while core segments (Yuyuan and Fosun Tourism Segment) recorded net profit attributable to owners of the parent of RMB 320 million, up by 50% YoY 13.95 Billion/RMB The overseas revenue accounted for 44.1% of the total revenue, up by 3 ppts YoY Club Med operates in 40+ countries and regions across six continents, with strong global operating capabilities and a continuously increasing share of overseas revenue 2026H1 Total Revenue Net Profit 160 Million/RMB YoY Growth 157.2% Happiness Segment Business Highlights 1. Financials 2. Business 2.2 Happiness 3. Strategic Development 31.63 Billion/RMB Yuyuan Revenue: 17.02 Billion/RMB Globalization – Overseas Revenue Revenue: 9.92 Billion/RMB
Page 27
2727 Yuyuan • In 2026H1, operating revenue reached RMB 17.02 billion, and net profit attributable to owners of the parent hit RMB 160 million • The company actively advanced business transformation and innovation, accelerated product mix optimization and enhanced channel quality. Gross profit margin reached 18.6%, up by 4.5 ppts YoY Yuyuan: Resilient Strategic Transformation, Significant Improvement in Gross Profit Margin Gross Profit Margin 469.2 363.7 191.1 170.2 2024 2025 2025H1 2026H1 12.2% 11.4% 14.1% 18.6% 2024 2025 2025H1 2026H1 8.3% 8.3% 7.3% 8.6% 2024 2025 2025H1 2026H1 Shede Spirits’ E-commerce Revenue Unit: 100 Million/RMB 2.56 3.36 3.98 2024H1 2025H1 2026H1 Jewelry & Fashion • In 2026H1, the Jewelry & Fashion segment generated revenue of RMB 10.61 billion, down 17.1% year on year. • The company proactively responded to market changes, driving a leap in product competitiveness through a series of initiatives including deepening the "Good Fortune" brand positioning, strengthening the brand's cultural core, and focusing on intangible cultural heritage craftsmanship. Together with accelerated global expansion, this lifted gross profit margin by 1.3 percentage points to 8.6%, demonstrating strong operational resilience. Shede Spirits • In 2026H1, Shede Spirits achieved an operating revenue of RMB 2.287 billion and net profit attributable to owners of the parent was RMB 145 million • Sales revenue of regular baijiu products, represented by T68 Tuopai Exceptional, grew by 12% YoY. The company accelerated online channel development, with the launch of the “Zizai” 29% ABV baijiu and cultural-themed offerings, driving 18% YoY growth in online e-commerce sales revenue • Actively pursuing international expansion, Shede Spirits now covers 43 countries and regions across five continents, with 1,700 overseas retail endpoints 1. Financials 2. Business 2.2 Happiness 3. Strategic Development Operating Revenue Unit: 100 Million/RMB Jewelry & Fashion Gross Margin
Page 28
2828 Product-Driven • Based on deep consumer insights and research, we continue to cultivate the "Good Luck" brand mindset, build a highly competitive product matrix, and steadily reshape brand pricing power. In the first half of the year, the sales proportion of Lao Miao brand's per-piece pricing products exceeded 18%. • Deepening industry-research collaboration, we strengthen the brand's cultural core via the path of "Good Luck as the spirit, Intangible Cultural Heritage as the form". We build an exclusive craftsmanship moat from the source of R&D and supply chain, amplify cultural premium through terminal scenario upgrades, and form an optimized closed loop through full-lifecycle product management. The entire chain of "cultural value + craftsmanship barriers + scenario experience + data closed loop" works in synergy. • Relying on digital-intelligent capabilities, we build a precise and efficient supply chain system, focusing on intangible cultural heritage craftsmanship to drive product power leaps. We build a supplier capability profiling search engine to empower business decisions with data. We continuously expand product supply, pushing the number of shared inventory SKUs from over 1,400 at the beginning of the year to over 8,000. Yuyuan: Enhancing Quality and Efficiency in Jewelry Fashion, Multi- dimensional Operational Innovation Globalization Layout • Accelerating international business layout. As of June 2026, Lao Miao's stores in Hong Kong, Macau, overseas, and duty-free channels have expanded to 15, with significant sales growth. Going forward, we will focus on core market development, explore emerging markets, and build a diversified business map. Malaysia Pavilion Flagship Store Macau Sands Venetian Flagship Store 1. Financials 2. Business 2.2 Happiness 3. Strategic Development "co - branded collections with Heaven Official's Blessing "Ma Shang You Mi “ (Golden Rice) Collection
Page 29
2929 Yuyuan: Elevating the Grand Yuyuan Strategy with ICH at Its Core Integrated Destination Experience3 Becoming a global showcase for intangible cultural heritage (ICH) and fashion culture, integrating culture, commerce and tourism to create an immersive global destination for culture and commerce Jewelry & Fashion District2 ICH as the Strategic Priority 1 The Yuyuan Horse Year Lantern Festival connected the entire Grand Yuyuan area for the first time, with visitor traffic up by 10% YoY Leveraging the Lantern Festival and the Blooming in Grand Yuyuan as key events to establish public awareness of “Grand Yuyuan” for the first time Strategic priority – ICH as core focus Integrating ICH across the entire product, content and marketing ecosystem Focus on ICH – Redefining Grand Yuyuan An immersive destination of culture, commerce and tourism Global integration – Connecting Chinese and global ICH Connecting China and the world through ICH Yuyuan Phase I: Rapid gathering of leading brands to build a heritage-gold ecosystem Dunhuang Gold, First Store in ShanghaiJEMPER, First Store in Shanghai BFC: An Incubation Hub for Designer Jewelry Brands CIGALONG LinShiaoTung Frost DiamondCIRCLE 1. Financials 2. Business 2.2 Happiness 3. Strategic Development
Page 30
3030 Club Med: Deepening Its Global Presence and Enhancing the Resort Experience Club Med operates sales and marketing activities across 40+ countries and regions spanning six continents. As of July 30, 2026, it had 69 resorts in operation worldwide Club Med continued to expand its global destination footprint and enhance resort experiences. Club Med Urban Oasis Hangzhou Longwu Resort officially opened in April 2026, while Club Med South Africa Beach & Safari Resort soft-opened in July 2026 Club Med South Africa Beach & Safari Resort Club Med Urban Oasis Hangzhou Longwu Resort 1. Financials 2. Business 2.2 Happiness 3. Strategic Development
Page 31
3131 Atlantis Sanya: Continuous Product Innovation with Strong Operating Growth Double-digit growth in revenue: Both revenue and ADR achieved double-digit growth in 26H1 Strong Growth in International Guest Revenue: Revenue from international source markets grew strongly and accounted for more than 10% of total revenue C Show 2.0 upgrade: Enhanced storytelling, acrobatics, stage design and lighting, driving continuous improvement in customer satisfaction Historical Share of Non -Room Volume 2026H1 Business Volume 2026H1 Average Occupancy Rate Unaudited data Business Highlights Submitted public REITs application materials to the CSRC and the SSE on March 26, 2026 Officially accepted by the SEE on March 30, 2026 Received feedback from the SEE on April 27, 2026 Progress on Public REITs Application 2017 Pacific Coast Builders Conference “Gold Nugget Award” 2018 World Travel Awards Asia’s Best Tourism Resort Destination Best MICE Destination 2018 World Waterpark Association Leading Edge Award 2019 China Construction Industry Association “Luban Prize” 2026 No. 7 Water Park Worldwide in 2026 by Blooloop, world's leading website for professionals in the visitor attractions sector 1. Financials 2. Business 2.2 Happiness 3. Strategic Development
Page 32
32
Page 33
3333 Total premium reached EUR 3.88 billion, +19% YoY; total premium for international business was EUR 1.04 billion, up by 12% YoY; international business accounted for 26.7%, delivering stable performance Net profit reached EUR 0.17 billion Maintained “A” ratings from S&P and Fitch; in July, S&P upgraded the outlook from “Stable” to “Positive” Core operating profit grew by 3% YoY Consolidated net income amounted to EUR 0.57 billion, up by 12.7% YoY The quality of credit assets was resilient, and the non-performing loan rate dropped to 2.2% Total premium rose by 52.2% YoY, among the fastest in the market Net profit reached RMB 780 million, up by RMB 570 million YoY Capitalizing on market trends, new business from variable products accounted for over 50%, achieving growth in both scale and value Total premium grew by 36.2% YoY, among the fastest in the market Net profit reached RMB 570 million Built a differentiated healthcare ecosystem covering full lifecycle, healthcare journey, health offerings and senior care, strengthened four key product models, and deepened focus on key customer segments and high-value markets Insurance Contract Revenue1 830 Million/USD Total premium reached USD 1.19 billion, up by 11.8% YoY, with continued improvement in structure of the portfolio and profit Net profit reached USD 90 million Moody’s Financial Strength Rating upgraded to A3 with a “Stable” outlook Wealth 84% 5% 11% Insurance Asset Management (Property) Asset Management (Investment) 2026H1 Total Revenue Excluding the impact of HAL’s divestment, revenue grew by 8% YoY, driven by revenue growth at Fosun Insurance Portugal and Peak Re The Wealth segment recorded industrial operating profit of RMB 2.96 billion, including RMB 2 billion from insurance segment, up by 40% YoY The overseas revenue reached RMB 24.48 billion, accounting for 89.6% of the total Wealth Segment Business Highlights 1. Financials 2. Business 2.3 Wealth 3. Strategic Development 27.31 Billion/RMB Fosun Insurance Portugal Peak Re Maintaining No.1 market share in Portugal Insurance Contract Revenue1 2.06 Billion/EUR Core Operating Profit2 1.21 Billion/EUR Millennium BCP Pramerica Fosun Life Insurance Total Premium 8.38 Billion/RMB Fosun United Health Insurance Total Premium 4.96 Billion/RMB Revenue 4.50 Billion/RMB Asset Management Number of New Equity Funds3: 5 Equity Fund AUM4: 43.047 Billion/RMB 1 Insurance Contract Revenue is under IFRS17 2 Net interest income combined with commission income, deducted by operating costs 3 Number of new equity funds is calculated based on registration completed with Asset Management Association of China 4 As of 2026/6/30, the net asset value in the funds management report (the total amount of the valuation and the remaining cashon the account) + the remaining subscribed callable amount of the fund under management according to the LPA - the overlapping part of the capital contribution of the master and sub-fund managed by the same manager
Page 34
3434 2026H1 4.0% Insurance Business Highlights 1. Financials 2. Business 2.3 Wealth 3. Strategic Development Global Footprints Overseas Insurers: Efficient operation is the bedrock for profit generation Domestic Insurers: Relying on Fosun’s ecosystem for rapid growth Total Premium: 52.7 Billion/RMB Fosun Insurance Portugal Total Premium (including investment contracts, excluding La Positiva) 27.1 Billion/RMB La Positiva Total Premium 4.0 Billion/RMB Pramerica Fosun Life Insurance Total Premium 8.4 Billion/RMB Fosun United Health Insurance Total Premium 5.0 Billion/RMB Peak Re Total Premium 8.2 Billion/RMB Steadily expand the business scale, continuously enhancing profitability level 92.0% 3.5% Combined Ratio1 Annualized Investment Yield2 Prudently manage risk exposure, with excellent performance in profitability 91.0% Combined Ratio1 Annualized Investment Yield2 Leverage ecosystem strengths, and focus on long-term value growth +45% New Business Value YoY 5,844 Contracts of Retirement Community Policy 5.4 Billion/RMB Full-Cycle Premium Create a new business model of health insurance +47% New Business Value YoY 3,484 Contracts of Retirement Community Policy 2.5 Billion/RMB Full-Cycle Premium 1 Non-life combined ratio: Insurance service cost/insurance service income (IFRS17 standard, deducting reinsurance) 2 The total investment yield is calculated excluding cash and exchange gains/losses
Page 35
3535 亚太区 聚焦高增长区域，包括以 创新方式进入新市场 Fosun Insurance Portugal: Steady Growth and Ongoing Global Expansion 1. Financials 2. Business 2.3 Wealth 3. Strategic Development International Business Footprint – Core Companies Direct Insurance – Europe Maintain a strong local market position in Portugal while continuously pursuing opportunities in Central and Eastern Europe Direct Insurance – Portuguese/Spanish-Speaking Markets Strengthen existing market share and further expand into new potential markets - In 2026H1, total premiums for domestic business reached EUR 2.84 billion, up by 21% YoY , maintaining leadership in the Portuguese market with 30% share › Through repricing and new business development, premiums of non-life insurance totaled EUR 1.31 billion, up by 7% YoY - Continuously deepening presence in Peru, Bolivia and Chile, achieving total premiums of EUR 0.60 billion in 2026H1, up by 10% YoY › Peru: Ranked 4th in premiums › Bolivia: Maintained 2nd in premiums › Chile: In its sixth year of operations, climbed to 8th in premiums - In Africa, maintained top market position across key markets: Angola (4th), Cape Verde (1st), Mozambique (3rd) - The Prosperity Company achieved total premiums of EUR 0.21 billion in 2026H1, up by 13% YoY
Page 36
3636 Focusing on core tracks including AI, embodied AI, semiconductor chips, biopharma, and consumption 2家2被投企业成功上市 2026H1 Investment Highlights Asset Management (Investment) Business Layout Global Footprints for Asset Management Platforms 1. Financials 2. Business 2.3 Wealth 3. Strategic Development HAFS European Asset Services Fosun Health Capital Equity Investment Platform Fosun RZ Capital Equity Investment Platform Fosun Capital Equity Investment Platform Fosun Wealth Securities Europe: Paref Asia: Idera North America: Four Trees South America: Rio Bravo Global Alternative Asset Management Platform New Investment Projects ~40 New Investment Amount ~1.5 Billion/RMB Portfolio Company IPOs 16 listed 10+ filed
Page 37
37
Page 38
3838 Intelligent Manufacturing Revenue grew by 14.6% YoY, driven by growth at Hainan Mining and Wansheng Industrial operating profit reached RMB 180 million, up by 54% YoY, mainly driven by profit growth at Hainan Mining 57% 43% Resources & Environment Technology & Intelligent Manufacturing Revenue growth was primarily driven by a 33.5% YoY increase in sales volume of core products Net profit attributable to parent was RMB 2.17 million, down YoY, primarily due to intense competition in the polymer functional additives industry, lower per-ton gross margin, and higher FX losses amid continued depreciation of foreign currencies against the RMB Revenue: 2.72 Billion/RMB Up by 12.6% YoY The lithium resources business contributed RMB 208 million in net profit attributable to owners of the parent, accounting for 40.4% Benefiting from higher crude oil prices and RMB 103 million in fiscal subsidy for tight gas, the oil and gas business contributed RMB 280 million in net profit attributable to owners of the parent, accounting for 54.5% Net Profit Attributable to Owners of the Parent: 510 Million/RMB Up by 83.4% YoY Intelligent Manufacturing Segment Business Highlights 1. Financials 2. Business 2.4 Intelligent Manufacturing 3. Strategic Development 2026H1 Total Revenue Hainan Mining 4.61 Billion/RMB Globalization Wansheng Overseas Revenue: 1.2 Billion/RMB Revenue from overseas business accounted for 26.0% of the total Revenue: 1.97 Billion/RMB Up by 21.2% YoY
Page 39
3939 Hainan Mining: Strategic Resource Focus, Evolving from Cyclical to Growth 6.7 15.3 2025H1 2026H1 71.9 92.8 2025H1 2026H1 New Energy and Oil & Gas Synergies Drive Significant Growth 126.8 % Average Domestic LiOH 56.5% Spot Price Revenue Average Brent Crude Oil Spot Price Unit: USD/Barrel 7.30 ROIC (%)ROE(%) 5.26 29% Net Profit Attributable to Owners of the Parent 24.15 27.19 2025H1 2026H1 2.81 5.14 2025H1 2026H1 83.39% 12.58% Lithium Resources Business — A New Growth Engine Oil & Gas Business — Leveraging the Upcycle in Oil Prices to Increase Production Achieved attributable production of 6.424 million barrels of equivalent Weizhou 10-3 West Oilfield commenced production and achieved first oil production Continued to optimize existing resources, expand reserves and pursue high-quality M&A opportunities Advanced underground mining development to secure long-term resource supply Expanded sulfur concentrate sales, generating incremental net profit of approximately RMB 2.97 million Lump ore products maintained a gross margin above 47% Core strategy: Strengthen the foundation and pursue new growth Strategic positioning: A leading resource group anchored by traditional resources and driven by breakthroughs in emerging sectors Strategic Focus: Critical upstream resources for new energy and AI computing applications, including lithium and fluorite Shareholder returns: Annual cash dividend payout ratio of no less than 50% of annual net profit attributable to owners of the parent Full-scale production achieved, with lithium hydroxide output reaching 8,000 tons Established a vertically integrated value chain from overseas mining to domestic refining Commenced Phase II development of the Mali lithium mine, targeting 50,000 tons of attributable LCE capacity by 2030 Iron Ore Business — Lean Management to Strengthen the Foundation Strategic Leadership — Released the 15th Five-Year Strategic Plan Unit: 100 Million/RMB Unit: RMB 10,000/Ton 1. Financials 2. Business 2.4 Intelligent Manufacturing 3. Strategic Development
Page 40
4040 山东潍坊 Capacity Expansion Through Domestic Upgrades and Overseas Production Ramp-Up Continuous technological upgrades at domestic bases improved product quality， enhanced production efficiency, and supported steady capacity ramp-up Domestic Base Overseas Base The phosphate ester flame retardant project in Thailand base, the Group’s first overseas base, commenced operations, marking a major milestone in the globalization strategy and strengthening global supply chain resilience 山东潍坊 Steady Growth of Existing Businesses Deepening R&D Innovation and Accelerating Product Commercialization 133 90 94 141 93 84 Invention Patents Utility Model Patents Patent Applications Filed Dec 31, 2025 Jun 30, 2026 + 8 + 36.25 1.10 1.43 1.76 7.45 1.43 1.68 3.51 Polymer Functional Additives Organic Amine Coating Additives Raw Materials & Intermediates Sales Volume (10,000 tons) 2025H1 2026H1 + 19% + 18% + 99% + 30% Accelerating Pilot Production and Commercialization of New Products The PFAS-free, fluorine-free flame retardant for PC successfully completed pilot production; the nylon flame retardant entered mass production and sales; and multiple other new products are advancing through pilot production and gradually moving into commercial-scale production Deepening collaboration between industries, universities, and research institutes Collaborated closely with leading research institutions and universities, including the Chinese Academy of Sciences and Qingdao University of Science and Technology, to drive technological advancement and industrial upgrading 169 480 1000 1500 2000 2024 2025 2026 2027 2028 Sales Volume of Copper Clad Laminate Flame Retardants (ton) + 184% + 5 0 % per year Rapid Growth of New Products 304 1407 2025H1 2026H1 Sales Volume of Household Surfactants (ton) + 362 % Sales volume increased from 187 tons in 2025H1 to 374 tons in 2026H1, up by 100% YoY Sales volume figures for 2026- 2028 are forecasts and do not constitute commitments to investors Wansheng: The World’s Leading New Functional Materials Enterprise 1. Financials 2. Business 2.4 Intelligent Manufacturing 3. Strategic Development
Page 41
4141 Table of Contents Financials01. Business02. Strategic Development03.
Page 42
4242
Page 43
4343 1. Financials 2. Business 3. Strategic Development 3.1 Mission High-Quality Mission Vision Mission
Page 44
4444 Strategic Focus Mid-Term Goal Long-Term Goal Good Products Good Content Good Models Good Scenarios Profit Improvement 10 RMB Billion Asset Optimization Rating Upgrade Mid-term goal of the Group’s net profit attributable to owners of the parent Group interest-bearing debt <60 RMB Billion Rating Investment Grade 1. Financials 2. Business 3. Strategic Development 3.2 Strategy A Global Innovation-Driven Family Consumer Group High-Quality Strategy
Page 45
4545 Global R&D Fosun Pharma 3,000+ Global R&D personnel • Established highly efficient international R&D teams in China, the U.S., India and other countries • Connected with outstanding scientific talent worldwide through multiple collaboration models, including in-house R&D, co-development, licensing-in and deep incubation • In 2026H1, entered into an global exclusive option agreement with AriBio for AR1001, an innovative oral drug candidate for Alzheimer’s Disease Global Production Hainan Mining ~50% Share of overseas assets • Established a stable global resource network covering iron ore, oil and gas, and lithium across China, Mali in West Africa, Oman in the Middle East, Southeast Asia and other regions • In 2026H1, a total of 70,000 tons of lithium concentrate from the Bougouni Lithium Mine in Mali, Africa was shipped to Hainan. Lithium hydroxide production reached 8,000 tons, achieving a closed-loop industrial chain spanning overseas mining and domestic refining Product Strength 1. Financials 2. Business 3. Strategic Development 3.3 Operations High-Quality Operations: Global Development Market Strength Global Operations Global Marketing Fosun Health • Four hospitals in the Greater Bay Area have established international medical centers, with international healthcare business growing rapidly, recording 98% YoY growth in the first half of 2026 • Established multiple overseas offices, with partners covering Hong Kong and Macao, Southeast Asia, Central Asia and the Middle East, further strengthening the cross-border healthcare collaboration network Fosun Insurance Portugal ~30% Share of overseas premiums (excluding Portugal itself) • Market leader in Portugal with 30% market share. In 2026H1, domestic premiums increased by 21% YoY • Extensive presence across Portuguese-speaking markets in Europe, Africa and Latin America, ranking among the market leaders in premiums in Peru, Bolivia, Chile and other markets 140+ countries and regions Patients served
Page 46
4646 R&D Innovation Hetronifly® (Serplulimab) The world’s first anti-PD-1 monoclonal antibody approved for first-line treatment of small-cell lung cancer and the first approved for a perioperative gastric cancer indication HLX 43 The world's first PD-L1 ADC to enter Phase II clinical trials, with the potential to become a best-in-class broad-spectrum anti-tumor ADC Product Innovation Silver Cross Through supply-chain innovation and deep collaboration with Chinese factories, launched three breakout products — Cove, Nia and Breez — driving the market share of high-end baby strollers in the UK to over 35% Process Innovation Fosun United Health Insurance The "Yilian Youmeng" critical illness insurance series breaks the traditional model that emphasizes payouts over prevention. By collaborating with leading Class III Grade A hospitals like Ruijin Hospital, it offers full- lifecycle health management to fill a market void. Scenario Innovation Lao Miao Jewelry Lao Miao Jewelry has developed a product portfolio based on Jiangnan ICH craftsmanship, continuously strengthening the cultural and artisanal value of its products and driving product upgrades. Jewelry gross margin increased significantly in the first half of 2026 Hainan Mining Through technical upgrading of the carbonization line, achieved flexible switching between lithium carbonate and lithium hydroxide production, enabling flexible output of multiple lithium salt products and better meeting diversified market demand Grand Yuyuan Grand Yuyuan leverages intangible cultural heritage (ICH) as a key asset, combining immersive experiences, youth-oriented expression and international communication to create a global showcase for ICH and fashion culture, while establishing a distinctive cultural landmark for the city Atlantis Sanya Atlantis Sanya completed an upgraded 2026 version of its C Show, successfully hosted the Atlantis Water World May Day Music Festival, established a sea turtle conservation and education center, and launched the signature “Dolphin Meet-and-Greet” experience 1. Financials 2. Business 3. Strategic Development 3.3 Operations High-Quality Operations: Innovation Driving
Page 47
4747 AI + Health AI + Happiness AI + Wealth AI + Intelligent Manufacturing Infrastructure development Scenario-based applications (targeted breakthroughs) Business process restructuring AI symbiosis Implement AI in specific business scenarios Embed AI into core workflows Redefine industry rules through AIDevelop AI agents and a digital foundation Shifting from "Business + AI" to "AI + Business," deepening AI applications across industries, and restructuring business processes and models Fosun Pharma: PharmAID® V2.0 covers the entire chain from decision-making, R&D and clinical trials to data. More than 25 AI projects have entered production, and two new-target molecules have entered the PCC stage Fosun Health: Launched the "Global Patient Smart Healthcare Service Platform for China In- bound Care," using AI-driven international patient referral and intake to compress the traditional process from 2–5 days to 1–2 hours Tourism Business: The AI travel agent AI G.O. provides personalized services covering the entire customer journey — before, during and after travel — across all scenarios and around the clock, reshaping the customer experience FOYO Commercial Management: The digital employee DataJoy AI serves core functions including tenant sourcing, operations and marketing, enabling employees to shift from "people searching for data" to "data finding people" Fosun United Health Insurance: Added 13 software copyrights and 18 invention patents, and implemented more than 34 AI application scenarios. Self-developed AI products such as “He Wu Ji" and "Lv Xing Jia" leverage digital and intelligent technologies to empower insurance services, reshape the claims experience, and improve quality and operational efficiency Hainan Mining: China's first iron ore beneficiation project to implement AI- powered intelligent photoelectric sorting technology, turning jigging tailings into valuable resources and effectively improving the utilization of low-grade iron ore resources Easun Technology: Developed a globally integrated collaborative AI agent development platform for scenarios such as engineering solution design, pre-sales response, supply chain intelligence and knowledge bases, significantly improving operational efficiency Fosun Insurance Portugal: Extended AI applications into core business decision- making processes, continuously improved the automation of claims processing, and advanced the restructuring of underwriting alongside compliance governance 1. Financials 2. Business 3. Strategic Development 3.3 Operations High-Quality Operations: AI Applications
Page 48
4848 Strengthen organizational support for business alignment. Build a Fluid Organization – Flexible Management, Choosing What Works Best; Build an AI-Enabled Organization - Strong AI Applications Phasing out Those Without • Align closely with business strategy, strengthen the positioning of the headquarters as an operational control hub driven by strategic finance, improve asset management efficiency, and build a high-performance organization • Emphasize AI adoption, reshape organizational relationships, foster a new AI-enabled organizational model, and drive the transformation of business processes and organizational structures • Accelerate globalization and build a truly global organization. Improve global governance and allocation • Gather top-level talent with entrepreneurship, targeting the development of ~160 Fosun Global Partners • Nurture and develop young talent for a pipeline of future leaders, with 117 young partners selected at the Group level since 2025 • Select and develop AI pioneers: Enable talent with both strong business insight and AI application capabilities to become a key driving force within the AI-enabled organization • Focus on business growth and problem-solving, supported by an efficient TC decision-making mechanism; rewards and penalties by campaign results, ranking-based mobility, shared gains through collaboration, and co-investment for innovation • Aligned with an entrepreneurial mindset, strengthen co-creation and shared incentive mechanisms based on incremental value • Strengthen a value-creation-oriented performance evaluation system to promote long-term alignment between management and shareholders Organization Global AI Symbiotic Organization Talent Multi-level Partner System Mechanism Campaign-oriented Culture Joint Entrepreneurship Spirit • Stay true to the “Joint Entrepreneurship” spirit, establish a partnership mechanism based on co- creating value, sharing risks, and sharing the results, building a global diversified business development system, and continuously strengthen cohesion and alignment • Adhering to the culture of “law, reason, emotion,” the Group places “law” at the core of global governance, safeguards shareholder rights as the baseline, and pursues maximization of shareholder value AI+ Business, AI + Organization Fosun BG Lines Departments Campaign Teams AMC Improvement in Productivity and Cost Efficiency Core Operating Profit Operating Cash Flow ROE ImprovementEfficiency Enhancement and Dividend Growth Market ShareGrowth Efficiency Value 1. Financials 2. Business 3. Strategic Development 3.4 Organizational Support High-Quality Organizations
Page 49
4949 E S G 2050 Carbon Neutrality Commitment & Mid-term Emission Reduction Target: By 2034, greenhouse gas emission intensity (Scope 1 and 2) to be reduced by 20% compared to 2024. Corporate Governance • Continuously optimizing/evolving enterprise risk management • Conducting double materiality assessments (financial and impact materiality) • Creating IMPACT sustainable development strategy • Top-down ESG governance structure, establishing an ESG Decision Committee and an ESG Management Committee • ESG performance incorporated into Board assessments, linked to CEO compensation • Promoting ESG culture across Fosun's domestic and overseas ecosystems • Close communication and engagement with external stakeholders • ESG reports verified by third parties annually (since 2021) EHS Management Framework: Integrating "carbon neutrality" as a key consideration into the EHS audit system, conducting annual group- level audits and member company self-audits. Climate Change Response: The fourth climate information disclosure report to be published in April 2026, enhancing disclosures with reference to HKEX, TCFD, and IFRS S2. ESG: Deepening Sustainable Practices, Continually Gaining Global Recognition Rural Doctors Guardian Program: Over nine years, covering 78 counties, safeguarding 25,000 rural doctors, and benefiting over 16 million rural residents. Supporting WHO in Combating Malaria: 40 anti-malaria product series certified by WHO-PQ; as of June 2026, artesunate has saved over 92 million severe malaria patients. Emergency Relief: Mobilizing multi-party resources, cumulatively dispatching over 1.19 million pieces of living and rescue supplies to Guangxi, Liaoning, Hubei, Hebei, and other regions. • MSCI ESG Rating upgraded to AAA • S&P Global Corporate Sustainability Assessment results continue to maintain a leading position among global peers • Selected for S&P Global Sustainability Yearbook 2026 and ranked in the top 1% of Sustainability Yearbook (China Edition) 2026 • Hang Seng Corporate Sustainability Rating maintained at AA- • Consecutively selected as a constituent of the Hang Seng Corporate Sustainability Benchmark Index (HSSUSB) • Consecutively selected as a constituent of the FTSE4Good Index Series • Fosun International has been awarded the "Asia-Pacific Sustainability Award" and "Best Environmental Responsibility Award" by Corporate Governance Asia magazine for multiple consecutive years Participation in Relevant Sustainable Organizations¹ 1 Organizations participated in by Fosun and/or Fosun member companies ESG Ratings & External Recognition 1. Financials 2. Business 3. Strategic Development 3.5 ESG
Page 50
5050
Page 51
5151 Fosun International 2026 Interim Results https://www.fosun.com https://ir.fosun.com Fosun WeChat Official Account Fosun IR WeChat Official Account Fosun Weibo Fosun Video Channel Fosun Douyin